EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieKohortenstudie

Nitrofurantoin Versus Comparators in the Treatment of Cystitis due to Extended-Spectrum β-Lactamase–Producing Enterobacterales: A Multicenter Cohort Study

Abrar K Thabit iD, Khalid Al Sulaiman iD, Lulwa Alfaraj, Sarah A Radwan, Layan O Almadfaa, Raneen H Mokhtar, Shuroug A Alowais, Khalid Bin Saleh, Khalid Eljaaly iD, Abdulmajeed A Alzahrani, Abdulaziz J Alshehri, Fadwa S Alofi und 1 weitere

Annals of Pharmacotherapy · 2025

DOI: 10.1177/10600280251315950 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Annals of Pharmacotherapy, 2025. Verfasst von Abrar K Thabit und 12 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Practice Department, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia. Hauptthemen laut MEDLINE: Cystitis, Nitrofurantoin, beta-Lactamases, Anti-Bacterial Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The increasing prevalence of extended-spectrum β-lactamase (ESBL)–producing bacteria has limited treatment options for cystitis. The recommendation of nitrofurantoin for treatment is based solely on in vitro studies.

Objective

We aimed to evaluate the effectiveness of nitrofurantoin versus comparators in treating cystitis due to ESBL-producing Enterobacterales in the clinical setting.

Methods

This was a multicenter retrospective cohort study of afebrile adults with symptomatic cystitis and a urine culture of ≥10 5 CFU/mL of ESBL-producing organism susceptible to nitrofurantoin and comparator antibiotics. Patients were categorized based on treatment (nitrofurantoin vs comparator). Clinical cure was the primary endpoint. Reinfection and relapse were secondary endpoints.

Results

Of 225 patients, 66 received nitrofurantoin and 159 received a comparator. Carbapenems were the most used comparator (57.2%). Clinical cure rates were not significantly different between the groups in crude (77.3% vs 86.2%; P = 0.101) and regression analyses (adjusted odds ratio [aOR], 0.82; 95% CI, 0.34-1.99). Of 35.4% of nitrofurantoin patients and 66.0% comparators group patients who had follow-up cultures, lower odds of relapse and reinfection were observed with nitrofurantoin, though not statistically significant (aOR, 0.28; 95% CI, 0.07-1.18 and aOR, 0.43 with 95% CI of 0.13-1.43, respectively). However, the inpatient setting was significantly associated with higher odds of relapse (aOR, 8.83; 95% CI, 1.07-72.74; P = 0.043). Conclusion and relevance: Nitrofurantoin was as effective as comparators in treating cystitis due to ESBL-producing Enterobacterales. The inpatient setting was associated with higher odds of relapse. Further larger research trials are needed to validate these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CystitisNitrofurantoinbeta-LactamasesAnti-Bacterial AgentsEnterobacteriaceae InfectionsEnterobacteriaceaeAnti-Infective Agents, UrinaryHumansFemaleRetrospective StudiesMaleMiddle AgedAgedCohort StudiesAdultTreatment Outcome

Stichwörter der Autor:innen

ESBLantimicrobial resistancecystitisnitrofurantoinurinary tract infection

Substanzen

Nitrofurantoinbeta-LactamasesAnti-Bacterial AgentsAnti-Infective Agents, Urinary

Autor:innen und Institutionen

  • Pharmacy Practice Department, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Pharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
  • College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
  • King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.
  • Saudi Critical Care Pharmacy Research Platform, Riyadh, Saudi Arabia.
  • Pharmacy Department, King Fahad Hospital, Jeddah, Saudi Arabia.

ORCID-Profile: Abrar K Thabit, Khalid Al Sulaiman, Khalid Eljaaly

Zitieren

APA

Thabit, A. K., Al Sulaiman, K., Alfaraj, L., Radwan, S. A., Almadfaa, L. O., Mokhtar, R. H., Alowais, S. A., Bin Saleh, K., Eljaaly, K., Alzahrani, A. A., Alshehri, A. J., Alofi, F. S., & Aljuhani, O. (2025). Nitrofurantoin Versus Comparators in the Treatment of Cystitis due to Extended-Spectrum β-Lactamase–Producing Enterobacterales: A Multicenter Cohort Study. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280251315950

Vancouver

Thabit AK, Al Sulaiman K, Alfaraj L, Radwan SA, Almadfaa LO, Mokhtar RH, et al. Nitrofurantoin Versus Comparators in the Treatment of Cystitis due to Extended-Spectrum β-Lactamase–Producing Enterobacterales: A Multicenter Cohort Study. Annals of Pharmacotherapy. 2025. doi:10.1177/10600280251315950

BibTeX
@article{Thabit2025,
  author = {Thabit, Abrar K and Al Sulaiman, Khalid and Alfaraj, Lulwa and Radwan, Sarah A and Almadfaa, Layan O and Mokhtar, Raneen H and Alowais, Shuroug A and Bin Saleh, Khalid and Eljaaly, Khalid and Alzahrani, Abdulmajeed A and Alshehri, Abdulaziz J and Alofi, Fadwa S and Aljuhani, Ohoud},
  title = {Nitrofurantoin Versus Comparators in the Treatment of Cystitis due to Extended-Spectrum β-Lactamase–Producing Enterobacterales: A Multicenter Cohort Study},
  journal = {Annals of Pharmacotherapy},
  year = {2025},
  doi = {10.1177/10600280251315950}
}
Kostenlos starten →